Gilead Sciences GILD Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $9.22B+8.3% | $8.51B+4.9% | $8.11B+28.5% | $6.31B+5.8% | $5.97B+1,143% | ||
| $903M+1.0% | $894M+0.9% | $886M+1.6% | $872M+1.8% | $857M+2.6% | ||
| —— | —— | -$97M+92.7% | -$1.33B-0.9% | -$1.32B+28.4% | ||
| —— | —— | $474M+2,357% | -$21M+92.6% | -$284M-104% | ||
| $865M-16.5% | $1.04B-9.0% | $1.14B+60.6% | $709M+17.4% | $604M+41.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $706M+1,402% | $47M+20.5% | $39M-63.9% | ||
| -$1.59B+24.8% | -$2.11B— | —— | —— | —— | ||
| $10.81B+7.9% | $10.02B+3.6% | $9.67B-2.0% | $9.87B-4.8% | $10.37B-4.3% | ||
| $576M+2.3% | $563M+11.5% | $505M+1.2% | $499M-4.4% | $522M-0.2% | ||
| $906M-15.3% | $1.07B+99.6% | $536M-42.9% | $939M-12.2% | $1.07B-77.9% | ||
| $4.18B+14.4% | $3.65B— | —— | —— | —— | ||
| -$2.61B+45.6% | -$4.79B-50.6% | -$3.18B+8.2% | -$3.47B-109% | -$1.66B+52.0% | ||
| $4.03B+0.7% | $4B+0.5% | $3.98B+0.6% | $3.96B+0.6% | $3.94B+0.5% | ||
| $1.61B-16.2% | $1.92B-5.9% | $2.04B+7.1% | $1.91B+28.9% | $1.48B+28.7% | ||
| $322M-21.1% | $408M-25.7% | $549M-0.2% | $550M+4.2% | $528M+25.1% | ||
| -$8.56B-10.5% | -$7.75B— | —— | —— | —— | ||
| $67M-30.9% | $97M+162% | $37M-54.3% | $81M+2,800% | -$3M+92.5% | ||
| —— | —— | —— | $2.37B-26.1% | $3.21B-17.9% | ||
| $2.39B-0.1% | $2.39B0.0% | $2.39B0.0% | $2.39B+0.1% | $2.39B+0.1% | ||
| $366M-1.1% | $370M-1.3% | $375M-1.1% | $379M-1.3% | $384M+0.8% | ||
| $318M+2.3% | $311M-26.1% | $421M+283% | $110M-47.6% | $210M-18.9% | ||
| -$572M-19.2% | -$480M-76.5% | -$272M-1.1% | -$269M+17.2% | -$325M+7.9% | ||
| $877M-14.3% | $1.02B+111% | $484M-40.9% | $819M+2.9% | $796M-83.0% | ||
| —— | —— | —— | —— | -$30M+48.3% | ||
| $136M+2.3% | $133M-15.8% | $158M+85.9% | $85M-13.3% | $98M-80.1% | ||
| $91M+65.5% | $55M— | —— | —— | —— | ||
| $3.37B+295% | $854M— | —— | —— | —— | ||
| -$443M-0.7% | -$440M-3.8% | -$424M-14.9% | -$369M-8.2% | -$341M-21.4% | ||
| $2.79B+56.2% | $1.79B+0.1% | $1.79B-5.4% | $1.89B-49.4% | $3.73B+89.4% | ||
| $10.23B+8.2% | $9.46B+3.2% | $9.16B-2.2% | $9.37B-4.8% | $9.84B-4.5% | ||
| $10.23B+8.2% | $9.46B+3.2% | $9.16B-2.2% | $9.37B-4.8% | $9.84B-4.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Gilead Sciences generate?
- Gilead Sciences (GILD) generated $10.8B in operating cash flow over the trailing twelve months.
- What is Gilead Sciences's free cash flow?
- After $576.0M of capital expenditures, Gilead Sciences's free cash flow was $10.2B over the trailing twelve months, up 3.9% year over year.
- Where does Gilead Sciences's cash flow data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
